Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 3/20 | 0.67 |
| ▸ | HTR2A | P28223 | 3/20 | 0.66 |
| ▸ | HTR1D | P28221 | 10/20 | 0.64 |
| ▸ | HTR1B | P28222 | 10/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2934047 | 0.97 | MPO (0.71) | MPOHTR2AHTR1DHTR1BHPGD | |
| SCHEMBL26508329 | 0.89 | HTR2A (0.65) | MPOHTR2AHTR1DHTR1BHTR1A | |
| SCHEMBL26508293 | 0.83 | HTR2A (0.70) | MPOHTR2AHTR1DHTR1B | |
| SCHEMBL26508359 | 0.83 | HTR7 (0.71) | MPOHTR2AHTR1DHTR1BHTR1A | |
| SCHEMBL26508375 | 0.83 | MPO (0.67) | MPOHTR2AHTR1DHTR1BHTR1A | |
| SCHEMBL26508389 | 0.83 | MPO (0.67) | MPOHTR2AHTR1DHTR1BHTR1A | |
| SCHEMBL26508398 | 0.83 | MPO (0.94) | MPOHTR2AHTR1DHTR1BHTR1A | |
| SCHEMBL26508379 | 0.83 | HTR1A (0.75) | MPOHTR2AHTR1DHTR1BHTR1A | |
| SCHEMBL3378557 | 0.80 | HTR1D (0.67) | MPOHTR1DHTR1BHTR1A | |
| SCHEMBL2933511 | 0.80 | HTR1A (0.75) | MPOHTR2AHTR1DHTR1BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322735-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322735-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322735-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | TPH2, TPH1, HTR2A | MPO 1224/4885HTR2A 3/4885HTR1D 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.